@genetic-counselor
Genetic Counselor
Forum Replies Created
-
Posts
-
The core clinical feature across all forms of spinal muscular atrophy is progressive, symmetric muscle weakness that is more pronounced in the proximal muscles (those closer to the trunk, such as the shoulders and hips) than in the distal muscles (hands and feet). Common symptoms include:
*Motor weakness and delayed milestones: Difficulty lifting the head, rolling over, sitting without support, standing, or walking, depending on age of onset.
*Hypotonia: Reduced muscle tone, often described as a “floppy” infant in early-onset cases.
Reduced or absent deep tendon reflexes.
*Tongue fasciculations: Fine, rippling movements of the tongue, seen in some infants with early-onset disease.
*Fine tremor of the fingers, sometimes noted in older children and adults with milder forms.
Respiratory muscle weakness: Weak cough, recurrent chest infections, and in severe cases, breathing difficulty, since intercostal muscles are affected more than the diaphragm.
*Bulbar weakness: Difficulty sucking, swallowing, or feeding, which can affect growth and nutrition in infants with severe disease.
*Skeletal complications over time: Scoliosis, joint contractures, and hip dislocation, resulting from prolonged muscle imbalance and reduced mobility.Importantly, spinal muscular atrophy does not affect intellect, sensation, or cognitive development. Children with even severe forms typically show normal alertness and social engagement, which is a distinguishing clinical feature that separates it from many other severe neurological conditions of infancy.
Spinal muscular atrophy is classified into types based on age of symptom onset and the highest motor milestone achieved. This classification also broadly correlates with SMN2 copy number, though exceptions exist.
*Type 0: Onset is prenatal to birth, and affected infants never achieve any independent motor milestone. Features include severe weakness at birth, reduced fetal movements, and often a need for ventilator support from birth; historically associated with very early mortality.
*Type 1 (Werdnig-Hoffmann disease): Onset is before 6 months of age, and affected children never sit independently. This is the most common and historically most severe postnatal form, marked by significant hypotonia and feeding and breathing difficulties.
*Type 2: Onset is between 6 and 18 months of age. Children sit independently but do not walk unaided. This intermediate form is associated with scoliosis and joint contractures developing over time.
*Type 3 (Kugelberg-Welander disease): Onset is after 18 months of age, and affected individuals walk independently at some point. This is a milder course, though the ability to walk may be lost later in childhood or adulthood in some individuals.
*Type 4: Onset is in adulthood, typically after age 21, with affected individuals walking independently. This is the mildest form, with slowly progressive proximal weakness that generally does not affect life expectancy.This classification remains clinically useful for prognosis and care planning, but with the availability of newer disease-modifying therapies, the distinctions between types are becoming less rigid, since early treatment can shift the natural trajectory a child would otherwise have followed.
The untreated natural history of spinal muscular atrophy varies substantially by type, reflecting the underlying difference in SMN2 copy number and residual protein production.
*Type 0 and Type 1: Historically, the natural history of untreated Type 1 disease showed a rapid and relentless decline in motor function after birth. Without ventilator or nutritional support, most infants with Type 1 did not survive beyond two years of age, with respiratory failure being the leading cause of death. Type 0 followed an even more severe course, with limited survival often measured in weeks to months.
*Type 2: Children typically achieve independent sitting but do not walk unaided. Motor function may appear to plateau for a period during early-to-mid childhood, but progressive weakness, scoliosis, and reduced pulmonary function often develop over years, and respiratory complications remain a significant concern into adulthood.
*Type 3: Individuals achieve independent walking, though the ability to keep walking varies. Some children lose ambulation during the school-age years or adolescence, particularly those with onset before age three, while others with later onset retain the ability to walk well into adulthood with gradually increasing fatigue and difficulty with stairs or running.
*Type 4: The disease course is slowly progressive over decades, with proximal weakness developing in adulthood. Respiratory and bulbar involvement are uncommon, and life expectancy is generally unaffected.Across all types, the natural history is shaped by the balance between ongoing motor neuron loss and the residual survival motor neuron protein produced by the SMN2 gene copies present in that individual. This is also why early genetic testing and SMN2 copy number analysis have become central to prognosis and to decisions around early therapeutic intervention, since starting treatment before significant, irreversible motor neuron loss has occurred is associated with meaningfully better outcomes than starting after symptoms are already established.
Genetic testing for spinal muscular atrophy is relevant in several distinct clinical situations:
*Diagnostic testing in a symptomatic infant or child: Any infant or child presenting with hypotonia, delayed motor milestones, or unexplained proximal muscle weakness should be evaluated for SMN1 gene deletion or mutation, since spinal muscular atrophy is one of the more common genetic causes of infantile hypotonia and a timely diagnosis directly affects treatment decisions.
*Carrier screening in couples planning a pregnancy or in early pregnancy: Since spinal muscular atrophy is autosomal recessive and carriers are asymptomatic, carrier screening can identify couples where both partners carry an altered SMN1 gene copy, allowing informed reproductive decision-making before or during pregnancy.
*Family history of spinal muscular atrophy: Relatives of an affected individual, particularly siblings of an affected child and individuals planning a family where a relative has been diagnosed, benefit from carrier testing to understand their own reproductive risk.
*Newborn screening programs: In regions where spinal muscular atrophy has been added to newborn screening panels, testing at birth allows identification before symptoms appear, which is particularly valuable given that early treatment initiation, before substantial motor neuron loss, is associated with better functional outcomes. Newborn screening for spinal muscular atrophy is expanding but not yet universal across India, so awareness among clinicians remains important for infants who may not have access to it.
*Prenatal diagnosis: For couples already known to be carriers, prenatal testing can determine whether a pregnancy is affected, allowing families to plan and prepare, including early referral to specialist care if the fetus is found to be affected.Genetic counseling is recommended alongside testing in each of these situations, so that individuals and families understand the implications of results, including residual risk, the meaning of SMN2 copy number when relevant, and the reproductive and clinical options available to them. Due to high carrier frequency of spinal muscular atrophy, carrier screening for spinal muscular atrophy is offered via deletion/duplication analysis as a primary screening for a couple seeking preconceptional counseling.
This depends on the family’s specific history, but it’s often considered earlier than standard screening guidelines if a close relative was diagnosed with cancer at a young age, or if multiple family members have had related cancers. A genetic counsellor can recommend a personalized starting point.
Yes, it can still be worthwhile. Many people are carriers of recessive conditions without any family history, since carriers themselves show no symptoms. General carrier screening can uncover risks that a family history alone wouldn’t reveal.
Yes. Recurrent pregnancy loss can sometimes be linked to chromosomal or genetic factors even when a couple has previously had healthy pregnancies, and testing can help identify a possible cause going forward.
Yes. Advanced parental age, especially maternal age, is associated with a higher chance of certain chromosomal conditions, making prenatal screening and diagnostic testing particularly relevant for this group.
Yes, especially with conditions that vary in severity or appear later in life. A sibling could carry the same gene change with milder or delayed symptoms, which is why testing close relatives is often recommended once a gene change is identified in the family.
Genetic testing has real value, but it is not absolute. A person can have a strong clinical picture of familial hypercholesterolemia, including very high cholesterol and a family history of early heart disease, and still test negative on a standard genetic panel, because not every gene change responsible for the condition has been identified or is included in current testing panels. In such cases, a negative genetic result does not rule out an inherited cause; the diagnosis may still be made on clinical grounds using cholesterol levels, family history, and physical findings. Additionally, genetic testing identifies risk based on known gene changes, but it does not measure the current severity of artery involvement, which still requires clinical and biochemical assessment. For this reason, genetic testing works best as one part of an overall evaluation rather than as a stand-alone yes-or-no answer, and results should always be interpreted by a clinician alongside the person’s cholesterol levels, family history, and cardiovascular risk profile.
Genetic testing for hypercholesterolemia is most useful for a person with very high low-density lipoprotein cholesterol despite a healthy lifestyle, a personal or family history of early heart attack or stroke, a family history of familial hypercholesterolemia, or a strong clinical suspicion based on cholesterol levels and physical examination findings. Testing is also valuable for first-degree relatives of someone already confirmed to carry a familial hypercholesterolemia gene change, since early identification allows treatment to start before arteries are significantly affected. In practice, a confirmed genetic diagnosis changes management by supporting earlier and more aggressive treatment decisions, guiding cascade testing of other family members, and providing clarity for long-term risk planning, including decisions around family planning. It also removes uncertainty for patients who might otherwise be told their high cholesterol is simply due to diet when the actual cause is inherited.
Diet- and lifestyle-related high cholesterol usually develops gradually, is influenced by factors such as saturated fat intake, physical inactivity, body weight, and other health conditions, and tends to respond reasonably well to lifestyle changes and standard doses of cholesterol-lowering medication. Familial hypercholesterolemia, in contrast, is present from birth, produces very high low-density lipoprotein cholesterol levels even in people with a healthy diet and normal weight, and often shows up as early heart disease in the person or their close relatives, sometimes before the age of fifty. Physical signs such as fatty deposits around the eyelids or in the tendons of the hands and Achilles tendon can also point toward the genetic form. Because the underlying mechanism is a faulty clearance pathway rather than excess intake, familial hypercholesterolemia usually needs a combination of high-intensity medication and, in some cases, additional targeted therapy rather than lifestyle change alone.
Yes, this is well established in medical literature. The clearest example is familial hypercholesterolemia, an inherited condition caused by changes in specific genes involved in how the body clears low-density lipoprotein cholesterol from the blood. The genes most commonly involved are LDLR, APOB, and PCSK9. A change in any one of these genes can prevent the liver from removing low-density lipoprotein cholesterol efficiently, leading to very high cholesterol levels from birth, well before diet or lifestyle factors come into play. Familial hypercholesterolemia follows a clear inheritance pattern within families, and children of an affected parent have a fifty percent chance of inheriting the same gene change. Beyond this single-gene form, research has also identified many common genetic variations that each contribute a small effect, together explaining why cholesterol levels tend to run in families even without a single identifiable gene change. So genetic contribution to high cholesterol is not a theory; it is a confirmed and well-studied mechanism.
Hypercholesterolemia refers to a condition in which the total cholesterol or the low-density lipoprotein cholesterol in the blood is higher than the recommended healthy range. Cholesterol itself is a fat-like substance that the body needs for building cell membranes, producing hormones, and making vitamin D, but when the low-density lipoprotein cholesterol fraction rises too high, it begins to deposit in the walls of arteries. Over years, this build-up narrows the arteries and increases the risk of heart attack, stroke, and peripheral artery disease. A normal cholesterol level is one where the low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride values fall within ranges considered safe for a person’s age and cardiovascular risk profile, whereas hypercholesterolemia represents a sustained elevation, usually of the low-density lipoprotein cholesterol, that raises long-term cardiovascular risk.
